GlassScriptPhysician profile
Ebony Lewis
NPI 1528502283
$4,406.60
in general payments reported to CMS, 2019-2025
25 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,343 · 2022: $730 · 2023: $1,318 · 2024: $909 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,090.62 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $599.46 | 2021-2023 | |
| Glaxosmithkline, LLC. | $405.70 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $330.45 | 2021 | |
| Phathom Pharmaceuticals, INC. | $262.32 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $240.10 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.08 | 2021-2024 | Stiolto Respimat, Jardiance, Spiriva Respimat |
| Abbott Laboratories | $236.76 | 2023 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $184.02 | 2023-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $157.49 | 2021 | |
| Exact Sciences Corporation | $121.80 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $118.09 | 2021 | |
| Lilly USA, LLC | $60.35 | 2021-2024 | Mounjaro |
| Hologic Sales and Service, LLC | $50.10 | 2021-2024 | Thinprep 2000 Processor |
| Dexcom, INC. | $44.29 | 2023 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.97 | 2021-2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Pfizer INC. | $40.10 | 2021-2023 | |
| Almatica Pharma LLC | $31.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.17 | 2022-2024 | Xifaxan |
| Mylan Specialty L.P. | $30.33 | 2021 | |
| Alkermes, INC. | $26.58 | 2023 | Vivitrol |
| Optinose US, INC. | $17.79 | 2024 | |
| Sunovion Pharmaceuticals INC. | $15.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.88 | 2021 | |
| Amarin Pharma, INC. | $14.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebony Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.